’
Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2’
WARREN, N.J., Sept. 03, 2025’ Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has taken significant strides in addressing the urgent need for effective SARS-CoV-2 treatments, particularly for individuals with compromised immune systems who are at the highest risk for severe complications related to COVID-19. The company’s investigational allogeneic SARS-CoV-2-specific Cytotoxic CD8+ T lymphocyte (CTL) immunotherapy, known as TVGN 489, has garnered attention for its potential to enhance immune responses in these vulnerable populations.
TVGN 489 utilizes the innovative ExacTcell platform, designed to fortify anti-SARS-CoV-2 immunity and directly target and eliminate the virus. A standout feature of this therapy is its ability to direct CTLs against the entire viral genome, as opposed to focusing on single viral proteins, thereby providing a more comprehensive immune response to the virus.
Recent data from positive point-of-care and dose-finding clinical trials of TVGN 489 has been published in the peer-reviewed journal ’Blood Advances’, further validating the therapeutic potential of this immunotherapy in immunocompromised individuals. These findings are particularly timely, as the COVID-19 pandemic continues to pose risks to those with weakened immune systems, including cancer patients, organ transplant recipients, and individuals living with HIV.
Despite a recent dip in the stock performance of Tevogen Bio Holdings Inc. in the broader market, the company has shown resilience over the past year, outperforming market averages. This trend attests to the growing confidence among investors in the company’s innovative approaches to precision immunotherapy.
As the global health landscape evolves, Tevogen’s emphasis on precision-based therapies like TVGN 489 highlights the critical need for targeted treatments for the most vulnerable. This not only reflects a commitment to advancing research in immunotherapies but also underscores an urgent public health imperative to protect those at the greatest risk from COVID-19 complications.
For additional information on Tevogen Bio and the latest research findings, visit their website or refer to the publication in ’Blood Advances’.
Comments